Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Condensed Consolidated Statements of Operations and Comprehensive Loss
Royalty income	$ 43,756	$ 41,500	$ 211,879	$ 117,153	$ 1,137,353
License fees		20,000		20,000	1,383,175
Milestone fees		150,000		150,000	150,000
Total revenues	43,756	211,500	211,879	287,153	2,670,528
Costs and expenses:
Research and development	915,457	511,433	2,661,551	1,326,197	20,111,002
Purchased in process research and development					2,666,869
General and administrative	2,205,952	739,042	5,391,932	2,375,666	31,312,048
Total operating expenses	3,121,409	1,250,475	8,053,483	3,701,863	54,089,919
Loss from operations	(3,077,653)	(1,038,975)	(7,841,604)	(3,414,710)	(51,419,391)
Interest income	44		44		266,927
Interest expense	(6,263)		(6,931)		(1,332,303)
Gain on sale of equipment					4,000
Amortization of deferred debt costs and original issue discount					(2,346,330)
Change in fair value of derivative instruments-warrants	(1,317,360)	388,750	(2,933,527)	(1,824,565)	(8,428,326)
Gain on extinguishment of debt					623,383
Liquidated damages and other forbearance agreement settlement costs					(1,758,111)
Net loss and comprehensive loss	(4,401,232)	(650,225)	(10,782,018)	(5,239,275)	(64,390,151)
Preferred stock dividend	(5,360)	(9,560)	(20,630)	(28,680)	(366,788)
Series A Convertible Preferred stock conversion rate change accreted as a dividend					(455,385)
Cumulative effect of early adopting ASC Topic 815-40					(792,956)
Net loss and comprehensive loss available to common stockholders	$ (4,406,592)	$ (659,785)	$ (10,802,648)	$ (5,267,955)	$ (66,005,280)
Net loss per common share-basic and diluted (in dollars per share)	$ (0.25)	$ (0.05)	$ (0.66)	$ (0.42)
Weighted average shares outstanding- basic and diluted (in shares)	17,870,703	14,178,733	16,330,313	12,506,789